Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Washington University in St. Louis · Teva Pharmaceuticals (United States) · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,166
total citations
- FWCI
- 79.48
- Percentile
- 100%
- References
- 38
Citations per year
Authors
10Topics & keywords
Topics
Keywords
- Medicine
- Benralizumab
- Placebo
- Asthma
- Internal medicine
- Clinical trial
- Mepolizumab
- Eosinophil
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.